Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05247684 | AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | active not recruiting | Phase 2 | 90 | AkesoINDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06445400 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 2 | 83 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06580054 | Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06854510 | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. | active not recruiting | Phase 2 / Phase 3 | 196 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03141359 | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | active not recruiting | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05599789 | Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)(KeyPemls-004) | active not recruiting | Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | active not recruiting | Phase 2 | 66 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | active not recruiting | Phase 2 / Phase 3 | 15 | Taiho Oncology, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06644768 | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | active not recruiting | Phase 1 / Phase 2 | 137 | Daiichi SankyoINDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06914687 | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04243616 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer(CemiHALT) | active not recruiting | Phase 2 | 36 | Medical College of WisconsinOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05538897 | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06944470 | JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC | active not recruiting | Phase 2 | 78 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02942355 | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03456843 | Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer | active not recruiting | Phase 2 | 190 | Yale UniversityOTHER | 6 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer(LOGICAN) | active not recruiting | Phase 2 | 118 | UNICANCEROTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02306954 | Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer | active not recruiting | Phase 2 | 84 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03247712 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 22 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | active not recruiting | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04413123 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | active not recruiting | Phase 2 | 60 | Bradley A. McGregor, MDOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT04166487 | Plasma-Adapted First-Line Pembro In NSCLC | active not recruiting | Phase 2 | 40 | Julia K. Rotow, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | active not recruiting | Phase 1 / Phase 2 | 200 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | active not recruiting | Phase 2 | 4 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04285671 | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05522985 | Toripalimab-based Neoadjuvant Therapy in LA-HNSCC | active not recruiting | Phase 2 | 122 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711470 | Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC(SCOPE) | active not recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02525757 | MPDL3280A With Chemoradiation for Lung Cancer | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | active not recruiting | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03225664 | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | active not recruiting | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03565783 | Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery | active not recruiting | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03599752 | Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04808999 | Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | active not recruiting | Phase 2 | 30 | Diwakar DavarOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2026source: clinicaltrials